Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) PT at $234.57

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average recommendation of “Moderate Buy” from the twenty-three brokerages that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $239.9444.

Several analysts have recently weighed in on IQV shares. Redburn Partners set a $214.00 target price on IQVIA in a report on Wednesday, September 3rd. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Citigroup boosted their target price on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a report on Wednesday, October 29th. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, Robert W. Baird set a $258.00 price target on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th.

IQVIA Stock Down 1.2%

IQV opened at $213.82 on Tuesday. The business’s 50-day simple moving average is $197.64 and its 200-day simple moving average is $174.62. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. IQVIA has a one year low of $134.65 and a one year high of $225.91. The stock has a market capitalization of $36.41 billion, a P/E ratio of 29.33, a price-to-earnings-growth ratio of 2.42 and a beta of 1.34.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the previous year, the business earned $2.84 EPS. The business’s quarterly revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts anticipate that IQVIA will post 10.84 EPS for the current year.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently added to or reduced their stakes in IQV. Canada Pension Plan Investment Board increased its position in IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after purchasing an additional 312,807 shares during the period. Alliancebernstein L.P. raised its stake in shares of IQVIA by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after buying an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA during the 2nd quarter worth approximately $515,772,000. JPMorgan Chase & Co. raised its stake in shares of IQVIA by 22.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after buying an additional 581,157 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of IQVIA by 12.3% during the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after buying an additional 253,759 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.